Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Is ALNY a good investment?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 85.0/100 as of May 27, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability leadership with ROE 96.9% and gross margin 80.8% vastly exceeding biotech peers. Main concern: High leverage risk with debt-to-equity ratio 2.51 vs industry average 0.63 creating financial vulnerability.
Investment Summary
ALNY presents a compelling growth story with exceptional profitability metrics (ROE 96.9% vs industry -32.9%, gross margin 80.8% vs -1.3%) and attractive growth-adjusted valuation (PEG 0.36 vs industry 1.29). Despite trading at premium P/E of 70.68 vs industry 38.48, the 78.2% five-year EPS growth projection justifies the valuation. Key concern remains high leverage (D/E 2.51 vs industry 0.63), but $3.0B cash provides cushion. Perfect news sentiment (100%) with management reaffirming $4.4-4.7B TTR revenue guidance supports investment thesis.
Key Strengths
- Exceptional profitability leadership with ROE 96.9% and gross margin 80.8% vastly exceeding biotech peers
- Significant undervaluation with PEG 0.36 vs industry 1.29 despite premium P/E reflecting superior growth quality
- Strong forward growth trajectory with 42.3% next-year and 78.2% five-year EPS growth projections
Key Concerns
- High leverage risk with debt-to-equity ratio 2.51 vs industry average 0.63 creating financial vulnerability
- Premium P/E valuation of 70.68 requires sustained high growth execution to justify current pricing
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ALNY demonstrates industry-leading profitability with ROE of 96.9% (vs industry -32.9%), gross margin of 80.8% (vs industry -1.3%), and net margin of 13.5% (vs industry losses of -551.6%). Growth prospects are exceptional with 42.3% next-year EPS growth and 78.2% five-year growth vs industry 22.95%. PEG ratio of 0.36 indicates significant undervaluation despite P/E of 70.68. Primary weakness is debt-to-equity of 2.51 (vs industry 0.63), though $3.01B cash provides substantial liquidity buffer. Free cash flow of $204.7M is positive but modest relative to company size.
News Sentiment
Alnylam Pharmaceuticals is riding high on strong commercial execution and unwavering management confidence in its blockbuster drug portfolio. The biotech giant recently reaffirmed its full-year revenue guidance of $4.4-4.7 billion for its TTR franchise, despite some sequential growth slowdown in Q1. CEO commentary highlighted robust access and prescriber growth for AMVUTTRA, positioning Vutrisiran as the first treatment option in its category for ATTR-CM patients. New clinical data presented at Heart Failure 2026 demonstrated consistent efficacy, further validating the company's scientific approach. The company's biggest moneymaker has been catapulting sales, with Q1 results topping both earnings and revenue estimates. This string of positive developments reflects Alnylam's successful transition from a research-focused biotech to a commercial powerhouse, with management's confidence suggesting the underlying business fundamentals remain rock-solid despite normal quarterly fluctuations.
Risk Assessment
Primary risk is high leverage (D/E 2.51) creating financial vulnerability if growth disappoints. Premium valuation (P/E 70.68) requires sustained execution. Mitigation: $3.0B cash cushion provides substantial buffer, and exceptional profitability metrics (ROE 96.9%) demonstrate strong cash generation capability. Biotech sector volatility adds risk but superior fundamentals vs peers provide relative protection.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ALNY a halal stock?
No, Alnylam Pharmaceuticals, Inc. (ALNY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 85.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ALNY a good investment?
According to Plutrex AI, ALNY has a Strong Buy rating (85.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ALNY?
US stocks like ALNY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ALNY?
Plutrex AI identifies the main risks for ALNY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.